Volume 7, Issue 2, June 2019, Page: 53-57
Clinico-Epidemiological Features and Survival Outcome in Patients with NSCLC: Ain Shams Clinical Oncology Department 5-Year Data
Ahmed Nagy, Department of Clinical Oncology and Nuclear Medicine, Ain Shams University Faculty of Medicine, Cairo, Egypt
Mohamed Kelney, Department of Clinical Oncology and Nuclear Medicine, Ain Shams University Faculty of Medicine, Cairo, Egypt
Received: Apr. 28, 2019;       Accepted: Jun. 10, 2019;       Published: Jun. 24, 2019
DOI: 10.11648/j.crj.20190702.14      View  180      Downloads  22
Abstract
Background: Primary lung cancer is the most common malignant neoplasm worldwide with various prognostic factors. Methods: Data was analysed retrospectively from the medical records of 504 patients diagnosed with NSCLC and treated at Department of Clinical Oncology and Nuclear Medicine, Ain Shams University, Cairo-Egypt in the period from 1-1-2008 till 31-12- 2012. Results: The Median PFS after first, second and third lines was 3, 4 and 2 months respectively and the median OS was 8 months. Factors which were associated with a statistically significant difference in median OS were: age<60 years versus≥60 years (10 and 7 months respectively, p<0.001), female versus male gender (10 and 8 months respectively, p<0.001), urban versus rural residence (9 and 8 months respectively, p=0.03), smokers versus non-smokers (8 and 10 months respectively, p<0.001), patients presenting with non-neurological symptoms and those presenting with neurological symptoms (9 and 6 months respectively, p<0.001) and the receiving treatment versus no treatment (10 and 5 months respectively, p<0.001). Conclusion: This study shows that the active treatment of patients with NSCLC continues to have an important impact on survival. The fact that rural residence could be associated with worse OS warrants further investigation.
Keywords
NSCLC, Adenocarcinoma, Lung, Cancer
To cite this article
Ahmed Nagy, Mohamed Kelney, Clinico-Epidemiological Features and Survival Outcome in Patients with NSCLC: Ain Shams Clinical Oncology Department 5-Year Data, Cancer Research Journal. Vol. 7, No. 2, 2019, pp. 53-57. doi: 10.11648/j.crj.20190702.14
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Siegel RL, Miller KD and Jemal A (2017): Cancer statistics, 2017. CA: a cancer journal for clinicians 67 (1), 7-30.
[2]
Charloux A, Hedelin G, Dietemann A, Ifoundza T, Roeslin N, Pauli G, Quoix E (1997): Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 17 (1), 123-134.
[3]
Rose MC, Kostyanovskaya E, & Huang RS. (2014): Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer. Genomics, Proteomics & Bioinformatics, 12 (5), 198–209.
[4]
Scagliotti, GV, De Marinis F, Rinaldi M, Crinò, L, Gridelli C, Ricci S. Italian Lung Cancer Project. (2002): Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 20 (21), 4285–4291.
[5]
Schiller JH, Harrington D, Belani C P, Langer C, Sandler A, Krook J, Eastern Cooperative Oncology Group. (2002): Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 346 (2), 92–98.
[6]
Socinski MA, Morris DE, G. A. Masters GA, and Lilenbaum R. (2003): Chemotherapeutic management of stage IV non-small cell lung cancer,” Chest, vol. 123, supplement 1, pp. 226S–243S.
[7]
Albain KS, Crowley JJ, LeBlanc M, and Livingston RB. (1991): “Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience,” Journal of Clinical Oncology, vol. 9, no. 9, pp. 1618–1626.
[8]
Videtic GMM, Stitt LW, and Stitt LW. (2003): Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. Journal of Clinical Oncology, vol. 21, no. 8, pp. 1544–1549.
[9]
Abbasi S and Badheeb A. (2011): Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy. Lung Cancer Int. 2011; 2011: 152125.
[10]
Stanley KE. (1980): Prognostic factors for survival in patients with inoperable lung cancer. Journal of the National Cancer Institute, vol. 65, no. 1, pp. 25–32.
[11]
Finkelstein DM, Ettinger DS, and Ruckdeschel JC. (1986): Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, vol. 4, no. 5, pp. 702–709.
[12]
Dela Cruz CS, Tanoue LT, & Matthay RA (2011): Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine, 32 (4), 605–644.
[13]
Cetin K, Ettinger DS, Hei YJ, O'Malley CD. (2011): Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 2011; 3: 139-48.
[14]
Ibrahim AS, Khaled HM, Mikhail N, Baraka H, Kamel H (2014): Cancer incidence in Egypt: results of the national population-based cancer registry program. Journal of cancer epidemiology 2014.
[15]
Blanchon F, Grivaux M, Asselain B, Lebas F, Orlando J, Piquet J, Zureik M.(2006): 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. The lancet oncology 7 (10), 829-836.
Browse journals by subject